203 related articles for article (PubMed ID: 34531368)
21. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
22. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
Prieur A; Tirode F; Cohen P; Delattre O
Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
[TBL] [Abstract][Full Text] [Related]
23. ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.
Gao Y; He XY; Wu XS; Huang YH; Toneyan S; Ha T; Ipsaro JJ; Koo PK; Joshua-Tor L; Bailey KM; Egeblad M; Vakoc CR
Nat Cell Biol; 2023 Feb; 25(2):298-308. PubMed ID: 36658219
[TBL] [Abstract][Full Text] [Related]
24. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.
Riggi N; Knoechel B; Gillespie SM; Rheinbay E; Boulay G; Suvà ML; Rossetti NE; Boonseng WE; Oksuz O; Cook EB; Formey A; Patel A; Gymrek M; Thapar V; Deshpande V; Ting DT; Hornicek FJ; Nielsen GP; Stamenkovic I; Aryee MJ; Bernstein BE; Rivera MN
Cancer Cell; 2014 Nov; 26(5):668-681. PubMed ID: 25453903
[TBL] [Abstract][Full Text] [Related]
25. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
26. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
27. Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer.
Gibori H; Eliyahu S; Krivitsky A; Ben-Shushan D; Epshtein Y; Tiram G; Blau R; Ofek P; Lee JS; Ruppin E; Landsman L; Barshack I; Golan T; Merquiol E; Blum G; Satchi-Fainaro R
Nat Commun; 2018 Jan; 9(1):16. PubMed ID: 29295989
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex.
Mo J; Tan K; Dong Y; Lu W; Liu F; Mei Y; Huang H; Zhao K; Lv Z; Ye Y; Tang Y
Oncogene; 2023 Jan; 42(1):11-25. PubMed ID: 36357572
[TBL] [Abstract][Full Text] [Related]
29. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
[TBL] [Abstract][Full Text] [Related]
30. Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1.
Neef R; Gruneberg U; Kopajtich R; Li X; Nigg EA; Sillje H; Barr FA
Nat Cell Biol; 2007 Apr; 9(4):436-44. PubMed ID: 17351640
[TBL] [Abstract][Full Text] [Related]
31. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
32. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
Carr RM; Vorobyev D; Lasho T; Marks DL; Tolosa EJ; Vedder A; Almada LL; Yurcheko A; Padioleau I; Alver B; Coltro G; Binder M; Safgren SL; Horn I; You X; Solary E; Balasis ME; Berger K; Hiebert J; Witzig T; Buradkar A; Graf T; Valent P; Mangaonkar AA; Robertson KD; Howard MT; Kaufmann SH; Pin C; Fernandez-Zapico ME; Geissler K; Droin N; Padron E; Zhang J; Nikolaev S; Patnaik MM
Nat Commun; 2021 May; 12(1):2901. PubMed ID: 34006870
[TBL] [Abstract][Full Text] [Related]
33. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
34. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
35. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
[TBL] [Abstract][Full Text] [Related]
36. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.
Grünewald TG; Bernard V; Gilardi-Hebenstreit P; Raynal V; Surdez D; Aynaud MM; Mirabeau O; Cidre-Aranaz F; Tirode F; Zaidi S; Perot G; Jonker AH; Lucchesi C; Le Deley MC; Oberlin O; Marec-Bérard P; Véron AS; Reynaud S; Lapouble E; Boeva V; Rio Frio T; Alonso J; Bhatia S; Pierron G; Cancel-Tassin G; Cussenot O; Cox DG; Morton LM; Machiela MJ; Chanock SJ; Charnay P; Delattre O
Nat Genet; 2015 Sep; 47(9):1073-8. PubMed ID: 26214589
[TBL] [Abstract][Full Text] [Related]
37. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.
Adane B; Alexe G; Seong BKA; Lu D; Hwang EE; Hnisz D; Lareau CA; Ross L; Lin S; Dela Cruz FS; Richardson M; Weintraub AS; Wang S; Iniguez AB; Dharia NV; Conway AS; Robichaud AL; Tanenbaum B; Krill-Burger JM; Vazquez F; Schenone M; Berman JN; Kung AL; Carr SA; Aryee MJ; Young RA; Crompton BD; Stegmaier K
Cancer Cell; 2021 Jun; 39(6):827-844.e10. PubMed ID: 34129824
[TBL] [Abstract][Full Text] [Related]
38. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
[TBL] [Abstract][Full Text] [Related]
39. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
de Cárcer G
Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30862113
[TBL] [Abstract][Full Text] [Related]
40. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
